Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.47
CORT's Cash to Debt is ranked lower than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CORT: 1.47 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1144.31 Max: No Debt
Current: 1.47
Equity to Asset 0.36
CORT's Equity to Asset is ranked lower than
82% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CORT: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.63 Max: 0.9
Current: 0.36
-0.1
0.9
F-Score: 7
Z-Score: 1.88
M-Score: -2.61
WACC vs ROIC
12.83%
-57.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -6.85
CORT's Operating margin (%) is ranked higher than
66% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. CORT: -6.85 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s Operating margin (%) Range Over the Past 10 Years
Min: -69827.59  Med: -1818.64 Max: -6.85
Current: -6.85
-69827.59
-6.85
Net-margin (%) -12.74
CORT's Net-margin (%) is ranked higher than
63% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. CORT: -12.74 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s Net-margin (%) Range Over the Past 10 Years
Min: -69537.93  Med: -1775.79 Max: -12.74
Current: -12.74
-69537.93
-12.74
ROE (%) -63.21
CORT's ROE (%) is ranked lower than
70% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. CORT: -63.21 )
Ranked among companies with meaningful ROE (%) only.
CORT' s ROE (%) Range Over the Past 10 Years
Min: -356.04  Med: -113.30 Max: -78.79
Current: -63.21
-356.04
-78.79
ROA (%) -13.84
CORT's ROA (%) is ranked higher than
62% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CORT: -13.84 )
Ranked among companies with meaningful ROA (%) only.
CORT' s ROA (%) Range Over the Past 10 Years
Min: -124.18  Med: -87.40 Max: -14.8
Current: -13.84
-124.18
-14.8
ROC (Joel Greenblatt) (%) -138.32
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CORT: -138.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -391957.14  Med: -49033.54 Max: -142.89
Current: -138.32
-391957.14
-142.89
Revenue Growth (3Y)(%) 135.50
CORT's Revenue Growth (3Y)(%) is ranked higher than
95% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CORT: 135.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CORT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 230.2
Current: 135.5
0
230.2
EBITDA Growth (3Y)(%) -57.00
CORT's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CORT: -57.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -16.85 Max: 4
Current: -57
0
4
EPS Growth (3Y)(%) -47.30
CORT's EPS Growth (3Y)(%) is ranked lower than
90% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CORT: -47.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.3  Med: -11.20 Max: 6.7
Current: -47.3
-47.3
6.7
» CORT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CORT Guru Trades in Q1 2015

Jim Simons 55,400 sh (New)
» More
Q2 2015

CORT Guru Trades in Q2 2015

First Eagle Investment 200,000 sh (New)
Jim Simons 501,614 sh (+805.44%)
» More
Q3 2015

CORT Guru Trades in Q3 2015

Paul Tudor Jones 21,279 sh (New)
Joel Greenblatt 17,221 sh (New)
David Swensen 22,334 sh (New)
First Eagle Investment 300,000 sh (+50.00%)
Jim Simons 452,200 sh (-9.85%)
» More
Q4 2015

CORT Guru Trades in Q4 2015

Paul Tudor Jones 27,099 sh (+27.35%)
Jim Simons 460,400 sh (+1.81%)
Joel Greenblatt 17,347 sh (+0.73%)
First Eagle Investment 300,000 sh (unchged)
David Swensen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 4810.00
CORT's Price/Owner Earnings (ttm) is ranked lower than
100% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. CORT: 4810.00 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CORT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3390  Med: 4320.00 Max: 5290
Current: 4810
3390
5290
P/B 28.44
CORT's P/B is ranked lower than
95% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. CORT: 28.44 )
Ranked among companies with meaningful P/B only.
CORT' s P/B Range Over the Past 10 Years
Min: 1.82  Med: 8.71 Max: 86.18
Current: 28.44
1.82
86.18
P/S 10.18
CORT's P/S is ranked higher than
53% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. CORT: 10.18 )
Ranked among companies with meaningful P/S only.
CORT' s P/S Range Over the Past 10 Years
Min: 7.18  Med: 190.00 Max: 1990
Current: 10.18
7.18
1990
POCF 165.89
CORT's POCF is ranked lower than
94% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. CORT: 165.89 )
Ranked among companies with meaningful POCF only.
CORT' s POCF Range Over the Past 10 Years
Min: 116.9  Med: 148.97 Max: 182.41
Current: 165.89
116.9
182.41
Current Ratio 2.35
CORT's Current Ratio is ranked lower than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CORT: 2.35 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 6.66 Max: 20.96
Current: 2.35
2.23
20.96
Quick Ratio 2.27
CORT's Quick Ratio is ranked lower than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CORT: 2.27 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 6.66 Max: 20.96
Current: 2.27
2.14
20.96
Days Inventory 389.08
CORT's Days Inventory is ranked lower than
90% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. CORT: 389.08 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 387.39  Med: 1093.61 Max: 2487.36
Current: 389.08
387.39
2487.36
Days Sales Outstanding 45.16
CORT's Days Sales Outstanding is ranked higher than
68% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. CORT: 45.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.16  Med: 48.08 Max: 61.48
Current: 45.16
45.16
61.48
Days Payable 355.35
CORT's Days Payable is ranked higher than
91% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. CORT: 355.35 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 3428.94 Max: 15257.8
Current: 355.35
355.35
15257.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 79.17
CORT's Price/Net Cash is ranked lower than
95% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. CORT: 79.17 )
Ranked among companies with meaningful Price/Net Cash only.
CORT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.55  Med: 8.18 Max: 83
Current: 79.17
2.55
83
Price/Net Current Asset Value 33.93
CORT's Price/Net Current Asset Value is ranked lower than
90% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. CORT: 33.93 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.47  Med: 7.94 Max: 35.57
Current: 33.93
2.47
35.57
Price/Tangible Book 27.94
CORT's Price/Tangible Book is ranked lower than
92% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CORT: 27.94 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.31  Med: 7.85 Max: 29.47
Current: 27.94
2.31
29.47
Price/Median PS Value 0.05
CORT's Price/Median PS Value is ranked higher than
98% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. CORT: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 0.21 Max: 1.34
Current: 0.05
0.06
1.34
Earnings Yield (Greenblatt) (%) -0.67
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CORT: -0.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -11  Med: 3588.90 Max: 3588.9
Current: -0.67
-11
3588.9

More Statistics

Revenue(Mil) $50
EPS $ -0.07
Beta1.49
Short Percentage of Float7.44%
52-Week Range $3.22 - 7.67
Shares Outstanding(Mil)109.66

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Corcept (CORT) Posts In-Line Q1 Earnings, Korlym in Focus May 04 2016
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 04 2016
Edited Transcript of CORT earnings conference call or presentation 3-May-16 9:00pm GMT May 03 2016
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update May 03 2016
Corcept beats 1Q profit forecasts May 03 2016
Corcept beats 1Q profit forecasts May 03 2016
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure May 03 2016
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update May 03 2016
Q1 2016 Corcept Therapeutics Inc Earnings Release - After Market Close May 03 2016
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host... Apr 29 2016
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host... Apr 29 2016
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134... Apr 28 2016
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134... Apr 28 2016
Corcept Therapeutics (CORT) Jumps: Stock Moves Up 9.6% Apr 01 2016
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics Mar 29 2016
ETF’s with exposure to Corcept Therapeutics, Inc. : March 28, 2016 Mar 28 2016
4 Surging Stocks Brokers Love in the Healthcare Sector Mar 28 2016
Can The Uptrend Continue for Corcept Therapeutics (CORT)? Mar 23 2016
CORCEPT THERAPEUTICS INC Financials Mar 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK